Related Experiment Videos
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Sattva S Neelapu1, Sudhakar Tummala2, Partow Kebriaei3
1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Nature Reviews. Clinical Oncology
|February 14, 2018
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Phenotype-Specific Associations Between Graft‑Versus‑Host Disease and Post‑Transplant Outcomes.
Transplantation and cellular therapy·2026
Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation.
British journal of haematology·2026
Exploring the landscape of targetable alterations in patients with glioblastoma.
Nature reviews. Clinical oncology·2026
AI-based augmentation of oncology clinical trials.
Nature reviews. Clinical oncology·2026
Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.
Nature reviews. Clinical oncology·2026
De-escalation trials in multiple myeloma: past, present and future.
Nature reviews. Clinical oncology·2026
Towards liquid biopsy-based analysis of antitumour immunity.
Nature reviews. Clinical oncology·2026
CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.
Nature reviews. Clinical oncology·2026
Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.
Human vaccines & immunotherapeutics·2026
CD7 CAR-T cells eliminate chronic myeloid leukemia stem cells specifically and effectively.
Hematology (Amsterdam, Netherlands)·2026
Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia.
Asia-Pacific journal of clinical oncology·2026